Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.
Authors
Haeseong Park
Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
Haeseong Park , Aravind Sanjeevaiah , Peter Joel Hosein , Rutika Mehta , Ramon Jin , Patrick Grierson , Rama Suresh , Olivia Aranha , Nikolaos A. Trikalinos , Nusayba Ali Bagegni , Katrina Sophia Pedersen , Kian-Huat Lim , Andrew B. Nixon , Jason Mills , Ryan Fields , Benjamin R. Tan Jr., Jingxia Liu , Amberly Brown , Andrea wang-gillam , A. Craig Lockhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03141034
DOI
10.1200/JCO.2022.40.4_suppl.284
Abstract #
284
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.
First Author: Haeseong Park
Poster
2020 Gastrointestinal Cancers Symposium
Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).
First Author: Daniel V.T. Catenacci
Poster
2020 Gastrointestinal Cancers Symposium
Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.
First Author: Akihito Tsuji
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz